Adding Personalized Patient-Centric Services, Transparency and Comprehensive Communications Improves Clinical Trial Performance, Says Clincierge®


  • Clincierge® to Highlight Success of Clinical Trial Recruitment and Retention-Boosting
    Services at World Orphan Drug Congress USA 2017


Philadelphia, PA (April 5, 2017): A high level of communication and personalized support for patients and caregivers can help overcome the often enormous challenges of patient recruitment and retention in orphan and rare disease clinical trials, according to Scott Gray, chief executive officer of Clincierge®.

Clincierge will be showcasing the company’s unique hospitality-driven services that support clinical trial recruitment and patient retention at World Orphan Drug Congress U.S.A 2017, being held in Washington D.C. from April 19 – 21. Additionally, Mr. Gray will chair the second day of the Main Conference, April 21.

“Patient recruitment and retention is an especially acute problem for rare and orphan disease clinical trials, as patients are widely dispersed and may face issues, such as physical limitations, that affect their ability to readily participate in trials,” said Mr. Gray. “As a result, clear and consistent communications and personalized, “high-touch” support for patients and caregivers can go far to ensure a high level of participation throughout even very lengthy studies.”

He noted that patients need to clearly understand the level of support that will exist for them throughout a study, especially for trials requiring multiple visits to distant study sites, so that the burdens of participation are not overwhelming.  “Knowing upfront that most of the logistical burdens and costs of trial participation will be handled for a patient and their family, and that there will be someone they can talk with by phone throughout the study in their own language and time zone can strongly encourage their enrollment,” Mr. Gray said.

“Sites, too, need to understand what support will exist for patients, separate from what they themselves offer,” Mr. Gray continued. He noted that rare disease trial sites play a large role in deciding which studies they will take on, and that decision is often made based on the “total package” of how the trial is designed and what services are being offered to patients upon enrollment that will help them to participate and remain on study through the full duration of the trial.

By overcoming burdens to patient enrollment in clinical trials and helping them to remain in the study despite the often significant challenges of continued participation, Clincierge’s unique hospitality-oriented services are reducing clinical testing time and cost, while improving the overall performance of clinical trials.

Clincierge Presence at World Orphan Drug Congress USA 2017

If you would like to know more about how Clincierge can improve the performance of your clinical trials, whether for rare or orphan diseases or for trials affecting larger numbers of patients, please visit our booth on the Exhibition Floor, #220, Washington Marriott Wardman Park Hotel.

About Clincierge®

Clincierge® reduces barriers to clinical trial participation, enhancing enrollment and reducing drop-outs. We help put patient needs first, providing personalized support, travel and accommodation logistics, and directly paying trial-related costs outside of reimbursable incidental expenses. One-on-one personal assistance in the patient’s own language helps answer study-related questions or concerns. We readily address special needs and complex trial designs, building custom solutions to specific study-related problems. We operate worldwide in 30 countries and 20 languages, adding service areas and capabilities as needed. Our goal: to reduce clinical testing time and cost, thus helping get new treatments to market as swiftly as possible. For more information on our company and services, please visit our website at



Kathy Murphy
Ph: +1-215-413-7881


For Media:

Joan Kureczka
Kureczka/Martin Associates
Ph: +1-415-821-2413